His primary scientific interests are in Internal medicine, Intensive care medicine, Retrospective cohort study, Pneumonia and Methicillin-resistant Staphylococcus aureus. His Internal medicine study incorporates themes from Surgery and Pediatrics. His Intensive care medicine study combines topics from a wide range of disciplines, such as Emergency department, Severity of illness, Epidemiology and Antibiotics.
The study incorporates disciplines such as Cohort study, Sepsis, Bacteremia, Intensive care unit and Drug resistance in addition to Retrospective cohort study. His research in Pneumonia is mostly focused on Ventilator-associated pneumonia. His research in Methicillin-resistant Staphylococcus aureus intersects with topics in Vancomycin and Antibacterial agent.
The scientist’s investigation covers issues in Intensive care medicine, Internal medicine, Pneumonia, Retrospective cohort study and Epidemiology. Andrew F. Shorr works mostly in the field of Intensive care medicine, limiting it down to topics relating to Emergency medicine and, in certain cases, Mechanical ventilation, as a part of the same area of interest. His Internal medicine research focuses on Surgery and how it relates to Vancomycin.
The Pneumonia study combines topics in areas such as Antibiotics, Methicillin-resistant Staphylococcus aureus and Drug resistance. In Retrospective cohort study, Andrew F. Shorr works on issues like Cohort, which are connected to Logistic regression. His research is interdisciplinary, bridging the disciplines of Incidence and Epidemiology.
Andrew F. Shorr focuses on Pneumonia, Intensive care medicine, Internal medicine, Epidemiology and Retrospective cohort study. His Pneumonia research incorporates elements of Antibiotics, Drug resistance and Sepsis. His Intensive care medicine study integrates concerns from other disciplines, such as MEDLINE, Antimicrobial, Fosfomycin, Anesthesiology and Antibiotic resistance.
His study in Surgery extends to Internal medicine with its themes. His Epidemiology research integrates issues from Census, Intensive care unit and Comorbidity. His biological study spans a wide range of topics, including Mechanical ventilation, Carbapenem, Respiratory failure, Emergency medicine and Confidence interval.
Andrew F. Shorr mainly investigates Pneumonia, Intensive care medicine, Ventilator-associated pneumonia, Epidemiology and Drug resistance. His Pneumonia study is related to the wider topic of Internal medicine. The Internal medicine study combines topics in areas such as Vancomycin, Iclaprim and Surgery.
The concepts of his Intensive care medicine study are interwoven with issues in Mixed infection, Antibiotic therapy, Antimicrobial, Anesthesiology and Coinfection. The Biostatistics research Andrew F. Shorr does as part of his general Epidemiology study is frequently linked to other disciplines of science, such as Standard error, therefore creating a link between diverse domains of science. In his research, Relative risk and Risk factor is intimately related to Respiratory failure, which falls under the overarching field of Drug resistance.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Christopher J. Lettieri;Steven D. Nathan;Scott D. Barnett;Shahzad Ahmad.
Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.
Richard G. Wunderink;Michael S. Niederman;Marin H. Kollef;Andrew F. Shorr.
Clinical Infectious Diseases (2012)
Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database.
Andrew F. Shorr;Ying P. Tabak;Aaron D. Killian;Vikas Gupta.
Critical Care Medicine (2006)
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
A F Shorr;J L Wainright;C S Cors;C J Lettieri.
European Respiratory Journal (2007)
Economic implications of an evidence-based sepsis protocol: Can we improve outcomes and lower costs?*
Andrew F. Shorr;Scott T. Micek;William L. Jackson;Marin H. Kollef.
Critical Care Medicine (2007)
Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study
Marya D Zilberberg;Andrew F Shorr;Scott T Micek;Cristina Vazquez-Guillamet.
Critical Care (2014)
Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
Ethan Rubinstein;Tahaniyat Lalani;G. Ralph Corey;Zeina A. Kanafani.
Clinical Infectious Diseases (2011)
Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia.
Andrew F. Shorr;Marya D. Zilberberg;Scott T. Micek;Marin H. Kollef.
JAMA Internal Medicine (2008)
Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies
Andrew F. Shorr;Mark J. Kunkel;Marin Kollef.
Journal of Antimicrobial Chemotherapy (2005)
Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis.
Andrew F. Shorr;Kevin Chung;William L. Jackson;Paige E. Waterman.
Critical Care Medicine (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: